Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Accured Expenses (2017 - 2025)

Aclaris Therapeutics has reported Change in Accured Expenses over the past 9 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $1.3 million for Q4 2025, down 89.19% from a year ago — trailing twelve months through Dec 2025 was -$8.1 million (down 105.4% YoY), and the annual figure for FY2025 was -$8.1 million, down 105.4%.
  • Change in Accured Expenses for Q4 2025 was $1.3 million at Aclaris Therapeutics, down from $1.3 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for ACRS hit a ceiling of $11.6 million in Q4 2024 and a floor of -$12.9 million in Q1 2024.
  • Median Change in Accured Expenses over the past 5 years was $657500.0 (2023), compared with a mean of $50700.0.
  • Biggest five-year swings in Change in Accured Expenses: skyrocketed 928.49% in 2023 and later tumbled 1012.67% in 2024.
  • Aclaris Therapeutics' Change in Accured Expenses stood at $2.5 million in 2021, then plummeted by 126.81% to -$681000.0 in 2022, then skyrocketed by 928.49% to $5.6 million in 2023, then skyrocketed by 105.1% to $11.6 million in 2024, then crashed by 89.19% to $1.3 million in 2025.
  • The last three reported values for Change in Accured Expenses were $1.3 million (Q4 2025), $1.3 million (Q3 2025), and $399000.0 (Q2 2025) per Business Quant data.